Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine and Cytarabine vs High-dose Cytarabine in CBF-AML
NCT02926586Phase 4Completed
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2017
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fludarabine in Core-binding factor acute myeloid leukemia (CBF-AML) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Percentage of participants with disease recurrence at 1 year. Started Jan 2017; status: completed.
02
Drugs
fludarabine
03
Conditions
Core-binding factor acute myeloid leukemia (CBF-AML)
Beyond the preview
Go deeper on NCT02926586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926586.